Purpose: Little has been published on the prognostic value of the Status Epilepticus Severity Score (STESS) or the Epidemiology-based Mortality score in Status Epilepticus (EMSE) in refractory status epilepticus (RSE). We sought to analyze the prognostic value of STESS and EMSE and the impact of baseline comorbidities in mortality and functional outcome in RSE. Methods: We designed an observational retrospective study of patients diagnosed with RSE between August 2013 and September 2017. For each patient, we analyzed prospectively recorded demographic, clinical, comorbidity, electroencephalographic, treatment, and hospital stay-related data and calculated STESS and EMSE. All variables were compared statistically between patients with good and poor functional outcome at discharge and between patients who died in hospital and those who were alive at discharge. Results: Fourty-nine patients had RSE; 35.4% died in hospital and 88% showed functional decline at discharge. Mortality was associated with baseline chronic kidney disease (CKD) (OR 19.25, p = 0.006), baseline modified Rankin scale score (mRS) (OR 3.38, p = 0.005), non-convulsive status epilepticus (NCSE) with coma (OR 11.9, p = 0.04), STESS (OR 2, p = 0.04), and EMSE (OR 1.3, p = 0.02). Functional outcome was associated with baseline mRS (OR 13.9, p = 0.02), and EMSE (OR 1.3, p = 0.02). The optimal cutoff scores for predicting mortality were 4 for STESS and 60 for EMSE. EMSE predicted functional outcome with an optimal cutoff of 40. Conclusions: CKD, NCSE with coma and STESS were associated with mortality. mRS and EMSE were associated with mortality and functional outcome. EMSE was useful for predicting functional outcome, while EMSE and STESS were useful for predicting in-hospital mortality.
Introduction
Refractory status epilepticus (RSE) is a life-threatening condition in which seizures do not respond to first and second-line antiepileptic drugs (AEDs) [1] . It usually requires the addition of a sedative drug. Super-refractory status epilepticus (SRSE) defines status epilepticus (SE) continuing after general anesthesia. RSE and SRSE are associated with severe systemic complications (cardiac arrhythmias, pneumonia, hypotension) [2] and high mortality, with rates of between 11.1% and 30% for RSE and 22%-50% for SRSE according to recent series [3] [4] [5] [6] [7] [8] [9] . Numerous factors have been associated with mortality and poor functional outcome in RSE, including age, etiology, acute symptomatic seizures, number of complications, cardiac and pulmonary complications, and seizure duration [10] [11] [12] [13] [14] [15] [16] [17] [18] . Associations with other comorbidities, such as chronic kidney disease (CKD), chronic liver disease, congestive heart failure, diabetes mellitus, chronic obstructive pulmonary disease, and oncologic disease have not yet been studied.
Two clinical scoring systems for predicting mortality in SE were recently introduced: STESS (Status Epilepticus Severity Score), which has four clinical components (level of consciousness, worst seizure type, age, and history of seizures) [19] , and EMSE (Epidemiology-based Mortality score in Status Epilepticus), which also has four components (etiology, comorbidity, age, and electroencephalography [EEG] ). The Charlson Comorbidity Index (CCI) takes morbidity into account and it is part of EMSE [20] . STESS ! 3 [19, 21] and !4 [22, 23] have been associated with mortality while EMSE ! 64 [24] has been described as a good predictor of both mortality and morbidity in SE.
Few studies have analyzed the ability of STESS or EMSE to predict mortality and functional outcome in RSE. Madzar et al. [14] indicated that STESS ! 3 was a potential predictor of long-term functional outcome in this setting, while Gaspard et al. [18] reported that STESS was associated with both mortality and poor functional outcome in patients with new-onset RSE. The prognostic value of EMSE has not been studied in RSE.
The aims of this study were to evaluate the association between demographic, clinical, comorbidity, and therapeutic data and functional outcome and mortality in RSE and to investigate the prognostic value of STESS and EMSE in this setting.
Methods

Patients
This was an observational retrospective study of consecutive patients diagnosed with RSE at Hospital Germans Trias i Pujol, a tertiary hospital in Barcelona, Spain, between August 2013 and September 2017. Patients aged 16 years or younger and patients with anoxic-ischemic SE were excluded. The study variables analyzed had been systematically entered into a prospectively managed database according to an established protocol. The study was approved by the local ethics committee.
SE was defined according the Report of the ILAE Task Force on Classification of Status Epilepticus as a condition resulting in either from the failure of the mechanisms responsible for seizure termination or from the mechanisms which lead to prolonged seizures. Nonconvulsive status epilepticus (NCSE) was defined as a continuous nonconvulsive seizure that lasts >30 min, or multiple nonconvulsive seizures during a period of >30 min and between which sensory, motor and/or cognitive function is not fully recovered [25] . According to ILAE Task Force on Classification of SE we classified NCSE in NCSE with coma and NCSE without coma. The last includes generalized NCSE (typical, atypical, myoclonic absence), focal without impairment of consciousness, aphasic status, focal with impairment of consciousness and autonomic SE [26] . RSE was defined as a SE who failed to respond to the administration of at least one first-line agent (benzodiazepine) and failed to respond to at least one second-line agent (phenytoin, valproate, levetiracetam, lacosamide or other urgent control AED). The time limit to consider that SE did not respond to AED was 30 min for convulsive SE and 60 min for non convulsive SE [27] . Patients were admitted in the intensive care unit and the third line agents were administered when convulsions or alteration of level of consciousness persisted despite first and second line of treatment. Third line agents are defined as continuous intravenous infusions of midazolam, propofol, and thiopental at maintenance doses alone or in combination sufficient to produce a burst suppression pattern on the EEG. Patients were daily monitored with a video EEG for at least two hours. The EEG monitoring was stopped 24 h after the third line agents were retired. In our hospital, patients with CPSE younger than 65 years old with a level of consciousness that was not in a coma or stupor were not admitted to the intensive care unit (ICU) and they were not routinely treated with anesthetics. These patients were optimized using FAES by combining two, three or four second line drugs if necessary. These patients only entered in the intensive care unit when there was a medical complication that required orotracheal intubation or when the CPSE lasted more than 48-72 h.
The following variables were collected for all patients: age and gender; premorbid functional status measured using the modified Rankin Scale (mRS) and the Glasgow Outcome Scale (GOS), with a score of 1-3 indicating poor outcome and a score of 4-5 indicating good outcome [28] ; presence, at the time of RSE diagnosis, of vascular disease (cerebrovascular disease, peripheral arterial disease, or ischemic heart disease), CKD ( [26] , summarized as generalized convulsive, focal convulsive, nonconvulsive SE (NCSE) without coma, and NCSE with coma; etiology (symptomatic or cryptogenic, depending on whether or not a cause was identified during follow-up: pharmacological transgression, cerebrovascular disease, brain tumor, central nervous system infection, traumatic brain injury, alcohol withdrawal, metabolic alterations); EEG findings according to the EMSE scoring system (spontaneous burst suppression, after SE ictal discharges, generalized periodic discharges, lateralized periodic discharges, none of these); number of AEDs used and need for sedative drugs; SE duration (days); and length of stay in intensity care unit (ICU) and in hospital (days). Functional outcome at discharge was assessed using the GOS. We consider as a worsening of the functional status the increase of one point or more of the GOS. In-hospital deaths were also recorded.
STESS and EMSE scores were calculated for all patients. STESS was calculated as follows: seizure type at presentation (simple partial, complex partial, or absence of seizures = 0 points, generalized convulsive seizure = 1 point, NCSE in coma = 2 points); history of seizures (yes = 0 points; no = 1 point), (age ! 65 years = 2 points; age < 65 years = 0 points), and level of consciousness at onset of SE (awake or somnolent = 0 points; stuporous or comatose = 1 point 
Statistical analysis
All variables were compared statistically between patients with good and poor functional outcome at discharge and between patients who died in hospital (non-survivors) and those who were alive at discharge (survivors). Data were collected and analyzed in SPSS version 18.0, and statistical significance was set at p 0.05. Descriptive statistics (mean AE SD and frequency tables) were used to analyze the main variables. Categorical and continuous variables were analyzed by the chi-square test and the t-test, respectively. Multiple regression analysis with the entry method was used to assess the independent effects of each variable on mortality and functional outcome at discharge. To analyze the ability of STESS and EMSE to distinguish between survivors and non-survivors and between patients with good and poor functional outcome at discharge we calculated the area under a receiver-operating characteristic (ROC) curve, which estimated the probability of a model assigning a higher risk of in-hospital mortality or poor functional outcome to those who were alive or had good functional outcome at the time of discharge. Youden's index was calculated to identify the cutoff point that optimized sensitivity and specificity for the prediction of outcomes. Sensitivity, specificity, positive and negative predictive values, and accuracy were calculated for the STESS and EMSE scoring systems.
Results
Eighty-one patients with non-hypoxic SE were identified. Of these, 48 (59%) had RSE. Of these patients with RSE, 12 (15% of total SE) had SRSE. The mean age of patients with RSE was 55.9 AE 18 years and 53.1% were male. Median (range) baseline mRS score was 2 (0-4) and median CCI was 2.5 (0-9). Over onethird of the patients (39.6%) had a history of seizures and 12.5% had a history of SE. Five patients (10%) had new-onset RSE. The most frequent comorbidities were vascular disease and CKD; present in 12 patients each (25%). Thirty-eight patients (79.2%) presented with stupor or coma and the main seizure type was partial, observed in 19 patients (40.8%). Most patients (85.4%) had a symptomatic etiology: 23.1% had a cerebrovascular disease, 15.4% metabolic alterations, 12.8% pharmacological transgression, 10% traumatic brain injury, 8.3% brain tumor, 7.7% had a central nervous system infection, and 5.1% of patients had a SE secondary to alcohol withdrawal. The EEG showed either lateralized or generalized periodic discharges in 28 patients (57.1%). Median STESS and EMSE were 3 (0-6) and 68 (2-154), respectively. A median of 3 AEDs (1-6) was required to achieve seizure control and 37 patients (75.5%) received at least one anesthetic drug. Reasons for not using anesthetic drugs were comorbidity (6 patients), NCSE (3 patients), and age (2 patients). Median RSE duration was 6 [2-66] days, median ICU stay was 11 , and median hospital stay was 25 days.
The in-hospital mortality was 35.4%. Of the 17 patients with RSE who did not survive, 8 had SRSE. The suspected cause of death of the 17 patients with RSE who died were: acute respiratory failure after bronchoaspiration in 7 patients, septic shock secondary to pneumonia in 4 patients, intracranial hypertension due to underlying etiology (brain tumor and cerebral hemorrhage) in 3 patients, congestive heart failure in 2 patients and intestinal ischemia in 1 patient. The majority of patients (88%) experienced worsening of functional status during hospitalization. At the moment of discharge, 35 patients (73%) had a GOS score of 1-3.
Factors associated with mortality in RSE
In the univariate analysis (Table 1) , the following factors were significantly associated with mortality: a higher baseline mRS score (p = 0.001) and CCI (p = 0.02), baseline CKD (p = 0.005), NCSE with coma (p = 0.002), and STESS and EMSE (p = 0.01 and p = 0.03 respectively).
The following factors were associated with an increased risk of mortality in the multivariate analysis (Table 2) : CKD (OR 16.25, p = 0.005), baseline mRS score (OR 3.03, p = 0.007), NCSE with coma (OR = 8.5, p = 0.03), STESS (OR = 2.6, p = 0.04), and EMSE (OR = 1.9, p = 0.02). STESS scale was related with mortality when the four components of the scale were included. If one of them was removed (level of consciousness, worst seizure type, age, or history of seizures) STESS scale was not associated with an increased risk of mortality (Data not shown).
Factors associated with functional outcome in RSE
In the univariate analysis (Table 3) , the following factors were associated with poor functional outcome at discharge: a higher The bold values are the statistically significant results. The bold values are the statistically significant results.
baseline mRS score (p < 0.001), higher EMSE (p = 0.04), the presence of lateralized or generalized periodic discharges in EEG (p = 0.006), and longer SE duration (p = 0.03). In the multivariate analysis (Table 4) , only baseline mRS score (OR = 9.1, p = 0.003) and EMSE (OR = 1.9, p = 0.04) retained their statistical significance. Among the survivors, patients with poor functional outcome at discharge had a longer hospital stay than patients with good functional outcome (13.34 vs. 12.35, p = 0.05).
Prognostic value of STESS and EMSE in predicting in-hospital death
The ROC curve for predicting in-hospital death in patients with RSE based on STESS had an area under the curve (AUC) of 0.717, with an optimal cutoff value for discrimination of !4 (best match for both sensitivity (Fig. 1). 
Prognostic value of STESS and EMSE in predicting functional outcome
STESS has no predictive capability for functional outcome (p = 0.7). In the case of EMSE, the ROC curve for predicting functional outcome had an AUC of 0.71, with an optimal cutoff of !40 (sensitivity [0.80] and specificity [0.75]) (Fig. 2) .
Discussion
The proportion of patients with RSE was 59%. It has been reported that SE duration, symptomatic etiology or greater consciousness impairment at baseline could be factors related to a poor prognosis or refractoriness in patients with SE. In our sample, the most frequent etiology was symptomatic (mainly cerebrovascular disease), most patients presented with stupor or coma and the SE duration was prolonged. We thought that all these factors could explain the high proportion of RSE found in our sample.
RSE is a serious neurological emergency associated with high mortality and high rates of functional decline [13] . The in-hospital mortality rate in our study was 35.4%, which is slightly higher than previously reported rates [15, [31] [32] [33] [34] [35] [36] , this might be explained by the inclusion of 12 patients with SRSE in the total number of RSE patients and this condition is associated with a bad prognosis. More than half of dead patients (10 of 17, 58%) died due to medical complications related to the RSE (7 for acute respiratory failure after bronchoaspiration and 4 for septic shock secondary to pneumonia). The rest died due to complications related to underlying etiology (intracranial hypertension secondary to brain tumor or cerebral hemorrhage) or other comorbidities. This data remarks the importance of optimizing the treatment of patients with RSE to avoid the complications of a prolonged ICU hospitalization.
The proportion of patients who experienced functional decline (88%) is higher than the rate of 59% described by Giovannini et al. [24] . This difference can be explained because we measured the functional status at discharge and Giovannini et al at 30 days post SE, so there is more time for patients to improve. The identification of risk factors and use of prognostic scales may help to improve outcomes in RSE by helping physicians to decide on the intensity of treatments depending on the patients' presenting condition.
To our knowledge, this is the first study to find that CKD in patients presenting with RSE is associated with a greater risk of inhospital death. Several mechanisms could have a role in this increased risk, including the increase of the plasmatic concentration in drugs excreted by the urinary system, such as lacosamide and levetiracetam, leading to the presence of more frequent adverse effects. On the other hand, the prevalent association between CKD and hypoalbuminemia results on a higher unbound drug level of widely used AED such as valproic acid and phenytoin that can enhance the likelihood of adverse effects. Other drugs widely used in ICUs and emergency departments, such as some antimicrobials and vasodilators can also deteriorate the renal function. Moreover, CKD is associated with increased risk for allcause and cardiovascular death due to the association with other risk factors such dyslipidemia, hypertension, smoking, and diabetes, and is associated with markers of inflammation and other putative risk factors for cardiovascular events, which might contribute directly to adverse outcomes [37] . Identification of CKD as a potential risk factor for mortality in RSE will help physicians to choose the most appropriate AEDs and other medications when treating in-hospital complications.
We also observed that the presence of NCSE with coma at diagnosis was associated with mortality. This is an important The bold values are the statistically significant results. The bold values are the statistically significant results.
finding as very few studies have investigated the prognostic value of clinical characteristics in the context of NCSE. Mortality risk in NCSE essentially depends on type of NCSE [38] , etiology (higher risk in acute symptomatic cases) [39] , age (higher risk in elderly people) [40] and seizure duration [41] . Baseline mRS score was associated with both mortality and functional outcome. This finding is consistent with reports by Gonzalez-Cuevas et al. [42] and reflects the role of comorbidities in SE outcome [12, 20, 41] . In our opinion, the addition of mRS scores to STESS remains a point of discussion, because even though a higher STESS may indicate the appropriateness of more intensive treatment, a high mRS score means that the patient already had poor functional status and could experience further functional decline or even die if treatment is intensified.
Our results regarding the ability of STESS and EMSE to predict mortality in patients with RSE are consistent with previous findings, and in addition, they indicate that EMSE is a useful tool for predicting functional outcome. To our knowledge, this has only been previously demonstrated for total status epilepticus [23] . Again, monitoring EMSE while a patient is in intensive care may help physicians to adjust the intensity of treatment accordingly.
Like other authors [22, 23, 43] , for STESS, we found that the optimal cutoff, with a sensitivity of 0.76 and a specificity of 0.64, to predict in-hospital mortality was !4 contrasting with the score of !3 proposed by the initial study [21] . It should be noted that the above-cited studies included all forms of SE, with no distinction between degrees of treatment refractoriness. One, retrospective, study concluded that STESS 3 or 4 can help to predict mortality [43] . The STESS scoring system has also been described as a useful scale for predicting functional outcome [23] . In the case of EMSE, we observed an optimal cutoff of !60 for predicting in-hospital mortality (sensitivity 0.82 and specificity 0.55) and !40 for predicting functional outcome (sensitivity 0.80 and specificity 0.75). According to a study by Kang et al. [23] , the best combinations of components from the EMSE system for predicting in-hospital mortality, with a cutoff of >60 and >81 respectively, were EMSE-ALDEg (age, loss of consciousness, duration, EEG) and EMSE-ECLEG (etiology, comorbidity, loss of consciousness, EEG). The best combinations, in turn, for predicting functional outcome at discharge were EMSE-ALDEg (>58 cutoff) and EMSE-ECLEg (>77 cutoff). Giovannini et al. [24] recently reported that EMSE (in particular, EMSE 64) appeared to be superior to STESS 3 and 4 for predicting 30-day mortality and morbidity. To our knowledge, our study is the first to report that the EMSE scale is useful for predicting both mortality and functional outcome in patients with RSE.
The main limitations of the present study are its single-center retrospective design and reduced sample size. Further multicenter and prospective studies are necessary to analyze the role of baseline comorbidities and the capacity of prognostic scales to predict long-term mortality and functional outcome in RSE.
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